Literature DB >> 9182114

Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection.

D Dutta1, S K Bhattacharya, M K Bhattacharya, A Deb, M Deb, B Manna, A Moitra, A K Mukhopadhyay, G B Nair.   

Abstract

An open randomised controlled clinical trial with 160 adults with acute watery diarrhoea and severe dehydration compared the efficacy of varying regimens of norfloxacin and doxycycline for the treatment of cholera caused by Vibrio cholerae 0139 Bengal. Data were analysed for the 111 patients who were faeces culture positive for V. cholerae 0139. In addition to rehydration therapy, 28 patients received 300 mg of doxycycline as a single dose on admission, 26 patients received norfloxacin 400 mg bd for three days, 28 patients received a single dose of 800 mg of norfloxacin and 29 patients received no antibiotic (control group). Patients in the three treatment groups and control group had comparable characteristics on admission. All three treatment groups had reduced stool output, duration of diarrhoea and fluid intake compared with the control group. Multidose norfloxacin treatment significantly reduced stool output, duration of diarrhoea and fluid requirement compared with the other regimens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9182114     DOI: 10.1093/jac/37.3.575

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India.

Authors:  P Garg; S Sinha; R Chakraborty; S K Bhattacharya; G B Nair; T Ramamurthy; Y Takeda
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  Management of infectious diarrhoea.

Authors:  A C Casburn-Jones; M J G Farthing
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

3.  Emergence of fluoroquinolone resistance in strains of Vibrio cholerae isolated from hospitalized patients with acute diarrhea in Calcutta, India.

Authors:  A K Mukhopadhyay; I Basu; S K Bhattacharya; M K Bhattacharya; G B Nair
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

4.  Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae.

Authors:  Somesh Baranwal; Keya Dey; T Ramamurthy; G Balakrish Nair; Manikuntala Kundu
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 5.  Antimicrobial drugs for treating cholera.

Authors:  Ya'ara Leibovici-Weissman; Ami Neuberger; Roni Bitterman; David Sinclair; Mohammed Abdus Salam; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2014-06-19

6.  Small Intestinal Infections.

Authors:  Saurabh Mehandru; Edmund J. Bini
Journal:  Curr Treat Options Gastroenterol       Date:  2001-04

7.  Comparison between Single Dose Azithromycin and Six Doses, 3 Day Norfloxacin for Treatment of Cholera in Adult.

Authors:  M K Bhattacharya; S Kanungo; T Ramamurthy; K Rajendran; A Sinha; A Bhattacharya; B Sharma Sarkar
Journal:  Int J Biomed Sci       Date:  2014-12

Review 8.  Role of antimicrobials in the treatment of adult patients presenting to the emergency department with acute gastroenteritis - A mini review.

Authors:  Omar Abbas Ahmed Malik
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

Review 9.  Global status of antimicrobial resistance among environmental isolates of Vibrio cholerae O1/O139: a systematic review and meta-analysis.

Authors:  Xin-Hui Yuan; Yu-Mei Li; Ali Zaman Vaziri; Vahab Hassan Kaviar; Yang Jin; Yu Jin; Abbas Maleki; Nazanin Omidi; Ebrahim Kouhsari
Journal:  Antimicrob Resist Infect Control       Date:  2022-04-25       Impact factor: 6.454

10.  Strategies to Prevent Cholera Introduction during International Personnel Deployments: A Computational Modeling Analysis Based on the 2010 Haiti Outbreak.

Authors:  Joseph A Lewnard; Marina Antillón; Gregg Gonsalves; Alice M Miller; Albert I Ko; Virginia E Pitzer
Journal:  PLoS Med       Date:  2016-01-26       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.